Headquartered in San Diego, CA Fiscal year ends December NASDAQ: SPRY ars-pharma.com
ARS Pharmaceuticals is a biopharmaceutical company commercializing neffy (epinephrine nasal spray), the first and only needle-free epinephrine option for emergency treatment of Type 1 allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. or greater. The product is approved in the United States and marketed under the trade name EURneffy in the EU and UK. The company targets a large addressable market of approximately 40 million people in the U.S. who experience Type 1 allergic reactions, of whom only 3.3 million have active epinephrine prescriptions. ARS Pharma is also advancing ARS-2, an intranasal epinephrine program for chronic spontaneous urticaria (CSU), currently in a Phase 2b trial. The company generates revenue through U.S. net product sales, international collaboration agreements, and supply agreements with partners. ARS Pharma trades on Nasdaq under the ticker SPRY. Updated
Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech stocks.
Are you looking for low-cost stocks to add to your portfolio? Doing so can be a challenge. After all, stocks that trade with low share prices are often risky investment opportunities. That’s…
Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying from an NFL team owner and a new CEO.
ARS Pharmaceuticals is a biopharmaceutical company commercializing neffy (epinephrine nasal spray), the first and only needle-free epinephrine option for emergency treatment of Type 1 allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. or greater.
The Wall Street consensus 12-month price target for SPRY is $22.50.
